Loading
Loading…
Loading…
| # | Company | Amount | Rank | Status |
|---|---|---|---|---|
| 1 | H1₹142.61Admitted-Finance | ₹142.61 | H1 | Admitted-Finance |
| 2 | H2₹117.53Admitted-Finance | ₹117.53 | H2 | Admitted-Finance |
| 3 | H3₹116.10Admitted-Finance | ₹116.10 | H3 | Admitted-Finance |
| 4 | H4₹46.88Admitted-Finance | ₹46.88 | H4 | Admitted-Finance |
| Sl No | Description | Qty | Unit | HETERO LABS LIMITED H1 | NATCO PHARMA LIMITED H2 | Mylan Laboratories Limited H3 | Zydus Healthcare Ltd H4 |
|---|---|---|---|---|---|---|---|
| 1.00ANTI TB DRUGS | |||||||
| 1.01 | Sofosbuvir 400 mg | 2,01,60,000 | Tablets | - | - | - | - |
| 1.02 | Daclatasvir 600 mg | 2,01,60,000 | Tablets | - | - | - | - |
| 1.03 | Sofosbuvir + Velpatasvir (FDC 400mg +100 mg) | 65,85,600 | Tablets | - | - | - | - |
Tender Value
₹134.3 Cr
EMD Value
₹16.7 L
Closing Date
18 Feb 2020, 2:00 pmClosed
DG and CEO
2nd Floor, Vishwa Yuvak Kenra, Near Teen Murti Marg
Procurement of Hep C drugs
2020_CMSS_536386_1
CMSS/PROC/2019-20/NVHCP/049
Open Tender
Drugs and Pharmaceutical Products
75 days
CMSS
As per Tender terms and conditions
2 documents required · 2 mandatory
₹0
₹16.7 L
Yes
New Delhi
22 May 2020
15 Jan 2020
18 Feb 2020
15 Jan 2020
18 Feb 2020
27 Jan 2020
15 Jan 2020 - 20 Jan 2020
20 Jan 2020
ANTI TB DRUGS
Sofosbuvir 400 mg
Daclatasvir 600 mg
Sofosbuvir + Velpatasvir (FDC 400mg +100 mg)
NATCO PHARMA LIMITED
Mylan Laboratories Limited
Zydus Healthcare Ltd
stage.html
html • 0.03 MB
tech_bid_open.pdf
tech_eval.pdf
fin_bid_open.pdf
boq_comp_chart.xlsx
xlsx
Tap a document below to read it instantly. You can also download everything as a ZIP if you prefer.
details.html
html • 0.03 MB
Tendernotice_1.pdf
PDF • 0.35 MB
TenderDoc_049.pdf
Tender Documents • 1.98 MB
BOQ_561809.xls
BOQ • 0.27 MB
Download all tender documents and submit your bid